Despite an impending patent cliff in 2026 that will invite generic competition from companies like Sun Pharma and Dr. Reddy’s, Emcure’s leadership believes the ‘innovator edge’ and a robust metabolic portfolio will secure long-term market dominance.
Despite an impending patent cliff in 2026 that will invite generic competition from companies like Sun Pharma and Dr. Reddy’s, Emcure’s leadership believes the ‘innovator edge’ and a robust metabolic portfolio will secure long-term market dominance. by Soban News (international And National News)
